# Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment

> **NCT02396862** · — · COMPLETED · sponsor: **Bayer** · enrollment: 272 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)

## Key facts

- **NCT ID:** NCT02396862
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-09
- **Primary completion:** 2018-01-17
- **Final completion:** 2018-03-26
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2019-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02396862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02396862, "Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02396862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*